Contemporary Treatment Paradigms are Associated with Improved Survival in Pancreatic Cancer.

Introduction: Over the last decade, a paradigm shift has been made in treating pancreatic cancer. Starting in 2011, several trials demonstrated a survival advantage for multiagent chemotherapy (MAC). However, the implication for survival at the population level remains unclear. Methods: A retrospective study of the National Cancer Database from 2006 to 2019 was conducted. Patients treated from 2006 to 2010 were classified as "Era 1", and those treated from 2011 to 2019 as "Era 2." Results: A total of 316,393 patients with pancreatic adenocarcinoma were identified, with 87,742 treated in Era 1 and 228,651 in Era 2. Survival increased from Era 1 to Era 2 in all patients and sub-analyses; surgical (18.7 vs 24.6 months, HR.85, 95% CI 0.82-.88, P <.001), imminently resectable (Stage IA and IB, 12.2 vs 14.8 months, HR.90, 95% CI 0.86-.95, P <.001), high-risk (Stage IIA, IIB, and III, 9.6 vs 11.6 months, HR.82, 95% CI 0.79-.85, P <.001), and Stage IV (3.5 vs 3.9 months, HR.86, 95% CI 0.84-.89, P <.001). Survival was decreased for those who were African American (P =.031), on Medicaid (P <.001), or in the lowest quartile of annual income (P <.001). Surgery rates decreased from 20.5% in Era 1 to 19.8% in Era 2 (P <.001). Discussion: Adoption of MAC regimens at a population level correlates with improved pancreatic cancer survival. Unfortunately, socioeconomic factors are associated with an unequal benefit from new treatment regimens, and underuse of surgery for resectable neoplasms persists. [ABSTRACT FROM AUTHOR]